Thomas R Kosten | Academic Influence

Thomas R Kosten's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Papers

Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. (861)
Background information and treatment recommendations for patients with HIV/AIDS (834)
Neurobiological Similarities in Depression and Drug Dependence: A Self-Medication Hypothesis (715)
Systematic Review: Opioid Treatment for Chronic Back Pain: Prevalence, Efficacy, and Association with Addiction (710)
Urinary Free-Cortisol Levels in Posttraumatic Stress Disorder Patients (416)
Prognostic significance of psychopathology in treated opiate addicts. A 2.5-year follow-up study. (372)
Management of drug and alcohol withdrawal. (358)
Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. (345)
Desipramine facilitation of initial cocaine abstinence. (340)
Nicotine dependence and schizophrenia. (314)
Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. (306)
The Neurobiology of Opioid Dependence: Implications for Treatment (288)
Prediction of dopamine transporter binding availability by genotype: a preliminary report. (286)
Cue-Induced Brain Activity Changes and Relapse in Cocaine-Dependent Patients (282)
A placebo controlled trial of bupropion for smoking cessation in schizophrenia (282)
Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder (277)
Buprenorphine versus Methadone Maintenance for Opioid Dependence (275)
Free radicals, antioxidant defense systems, and schizophrenia (238)
Concurrent Validity of the Addiction Severity Index (237)
Effects of Smoking Abstinence on Visuospatial Working Memory Function in Schizophrenia (232)
Gender differences in cocaine use and treatment response. (225)
A 2.5-year follow-up of depression, life crises, and treatment effects on abstinence among opioid addicts. (223)
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. (215)
Pharmacotherapy for Posttraumatic Stress Disorder Using Phenelzine or Imipramine (212)
A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. (211)
Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. (207)
Psychiatric disorders in relatives of probands with opiate addiction. (200)
Opioid dependence treatment: options in pharmacotherapy (189)
A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. (189)
Vaccine Pharmacotherapy for the Treatment of Cocaine Dependence (188)
Brief Report: Increased Addictive Internet and Substance Use Behavior During the COVID‐19 Pandemic in China (186)
Neural activity associated with stress-induced cocaine craving: a functional magnetic resonance imaging study (183)
Human therapeutic cocaine vaccine: safety and immunogenicity. (179)
A 2.5-year follow-up of cocaine use among treated opioid addicts. Have our treatments helped? (176)
Three Methods of Opioid Detoxification in a Primary Care Setting (175)
A randomized controlled trial of auricular acupuncture for cocaine dependence. (173)
Concurrent use of cocaine and alcohol is more potent and potentially more toxic than use of either alone—A multiple-dose study (166)
Elevation of Urinary Norepinephrine/Cortisol Ratio in Posttraumatic Stress Disorder (166)
A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. (160)
Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics (158)
Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. (153)
Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [123I] beta-CIT SPECT. (153)
Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial (152)
Differences between responders and nonresponders to cocaine cues in the laboratory. (150)
Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. (148)
Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. (129)
Cocaine abuse among opioid addicts: demographic and diagnostic factors in treatment. (127)
Should protracted withdrawal from drugs be included in DSM-IV? (127)
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: A call to action (125)
Clonidine in outpatient detoxification from methadone maintenance. (123)
Immunotherapy for the treatment of drug abuse. (122)
Neurobiological aspects of PTSD: Review of clinical and preclinical studies (121)
Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost. (121)
Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes (121)
Clonidine and naltrexone in the outpatient treatment of heroin withdrawal. (120)
Quantitative morphology of the caudate and putamen in patients with cocaine dependence. (119)
Buprenorphine detoxification from opioid dependence: a pilot study. (119)
Treatment Outcome Predictors for Cocaine Dependence (118)
Substance-Use Disorders in DSM-III-R (118)
Effects of progesterone treatment on cocaine responses in male and female cocaine users (117)
Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. (116)
Treatment of cocaine abuse with buprenorphine (116)
Novel Approaches to the Treatment of Cocaine Addiction (114)
Buprenorphine: Dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans (114)
Role of opioid antagonists in treating intravenous cocaine abuse. (113)
Gender differences in response to intranasal cocaine administration to humans (111)
Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. (111)
Gender differences in cognitive function of patients with chronic schizophrenia (110)
Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia (109)
Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings (109)
Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. (109)
Depressive symptoms during buprenorphine treatment of opioid abusers. (104)
Personality disorders in opiate addicts show prognostic specificity. (103)
BDNF Levels and Genotype are Associated with Antipsychotic-Induced Weight Gain in Patients with Chronic Schizophrenia (102)
Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. (102)
Novel pharmacotherapeutic treatments for cocaine addiction (101)
Disulfiram effects on acute cocaine administration. (100)
Emerging pharmacological strategies in the fight against cocaine addiction (100)
Cocaethylene: pharmacology, physiology and behavioral effects in humans. (100)
DSM-III personality disorders in opiate addicts. (100)
A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation (99)
Sex differences in brain activation during stress imagery in abstinent cocaine users: A functional magnetic resonance imaging study (97)
Noradrenergic dysregulation during discontinuation of cocaine use in addicts. (96)
Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients (96)
Depression as a prognostic factor for pharmacological treatment of cocaine dependence. (96)
Platelet alpha-granule release in cocaine users. (96)
Consensus statement on office-based treatment of opioid dependence using buprenorphine. (95)
Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. (95)
Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls (94)
Concurrent cocaine-ethanol ingestion in humans: pharmacology, physiology, behavior, and the role of cocaethylene (93)
Epigenetics of drug abuse: predisposition or response. (92)
Tryptophan depletion and attenuation of cue-induced craving for cocaine. (92)
Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase (90)
Prognostic factors in Buprenorphine- versus methadone-maintained patients. (90)
Vaccines Against Drug Abuse (90)
Performance of Cocaine Dependent Individuals and Controls on a Response Inhibition Task with Varying Levels of Difficulty (89)
Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. (89)
Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice (88)
Ethnic and gender differences among opiate addicts. (88)
The measurement of grief: bereaved versus non-bereaved. (88)
The dexamethasone suppression test and thyrotropin-releasing hormone stimulation test in posttraumatic stress disorder (87)
Rapid death during cocaine abuse: a variant of the neuroleptic malignant syndrome? (87)
Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics. (86)
Traditional Medicine in the Treatment of Drug Addiction (86)
Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. (85)
Treatment of patients with substance use disorders (83)
Antecedents and Consequences of Cocaine Abuse among Opioid Addicts: A 2.5‐Year Follow‐up (82)
HIV infection and cocaine use in methadone maintained and untreated intravenous drug users. (81)
Improving treatment outcome in pregnant opiate-dependent women. (80)
Treatment of heroin addicts using buprenorphine. (80)
Low BDNF is associated with cognitive deficits in patients with type 2 diabetes (79)
Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. (77)
Acute cocaine effects on absolute cerebral blood flow (76)
Depression and stimulant dependence: neurobiology and pharmacotherapy. (74)
Combating opiate dependence: a comparison among the available pharmacological options (74)
Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia. (73)
Success and Failure at Outpatient Opioid Detoxification: Evaluating the Process of Clonidine‐ and Methadone‐Assisted Withdrawal (71)
Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans (70)
Substance Abuse Vaccines (70)
Treatment of patients with substance use disorders, second edition. American Psychiatic Association. (70)
The novel oxidative stress marker thioredoxin is increased in first-episode schizophrenic patients (70)
Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics (69)
TREATMENT OF COCAINE ABUSE WITH MAZINDOL (69)
Pharmacogenetic Treatments for Drug Addiction: Alcohol and Opiates (68)
Association of Clozapine-Induced Weight Gain With a Polymorphism in the Leptin Promoter Region in Patients With Chronic Schizophrenia in a Chinese Population (68)
Strategies to improve compliance with narcotic antagonists. (68)
Effects of risperidone and haloperidol on superoxide dismutase and nitric oxide in schizophrenia (67)
The potential of dopamine agonists in drug addiction (67)
Acupuncture for the Treatment of Cocaine Dependence in Methadone-Maintained Patients (67)
Contingency management interventions: from research to practice. (66)
Significant interaction between clozapine and cocaine in cocaine addicts. (66)
Therapeutic vaccines for substance dependence (65)
Pharmacotherapeutic Interventions for Cocaine Abuse Matching Patients to Treatments (63)
Pharmacogenetic Treatments for Drug Addiction: Cocaine, Amphetamine and Methamphetamine (63)
Perfusion abnormalities and decision making in cocaine dependence (63)
Thrice-weekly versus daily buprenorphine maintenance (63)
Acupuncture for the treatment of cocaine addiction. Investigation of a needle puncture control. (62)
Buprenorphine for opiate addiction: potential economic impact. (62)
Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. (62)
Plasma total antioxidant status and cognitive impairments in schizophrenia (62)
Adjunctive desipramine in the treatment of cocaine abusing schizophrenics. (61)
Chronic disulfiram treatment effects on intranasal cocaine administration: Initial results (61)
Alprazolam and benzodiazepine dependence. (60)
Comparison of clinician ratings to self reports of withdrawal during clonidine detoxification of opiate addicts. (59)
Disrupted antioxidant enzyme activity and elevated lipid peroxidation products in schizophrenic patients with tardive dyskinesia. (59)
Opioid antagonist challenges in buprenorphine maintained patients. (58)
Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). (58)
Prediction of Treatment Outcome by Baseline Urine Cocaine Results and Self‐Reported Cocaine Use for Cocaine and Opioid Dependence (58)
A preliminary study of desipramine in the treatment of cocaine abuse in methadone maintenance patients. (58)
Effect of opioid dependence pharmacotherapies on zidovudine disposition. (58)
Antisocial personality disorder as a prognostic factor for pharmacotherapy of cocaine dependence. (57)
Psychopathology in opioid addicts. (57)
Differential diagnosis of psychiatric comorbidity in substance abusers. (57)
Stimulant withdrawal. (57)
Pharmacotherapy for opioid and cocaine abuse. (57)
Biological mechanisms in posttraumatic stress disorder. Relevance for substance abuse. (56)
Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment (55)
Stimulant withdrawal : Withdrawal syndrome (55)
Substance abuse and schizophrenia: editors' introduction. (55)
A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. (55)
Pharmacotherapy of cerebral ischemia in cocaine dependence. (55)
Mazindol treatment for cocaine dependence. (55)
Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. (53)
Office-based treatment for opioid dependence: reaching new patient populations. (53)
Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. (53)
Comorbid Major Depressive Disorder as a Prognostic Factor in Cocaine‐Abusing Buprenorphine‐Maintained Patients Treated with Desipramine and Contingency Management (52)
Cerebral perfusion defects in combined cocaine and alcohol dependence. (52)
Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia (52)
Serotonergic mechanisms of cocaine effects in humans (52)
Neurobiology of Abused Drugs: Opioids and Stimulants (52)
Interaction of BDNF with cytokines in chronic schizophrenia (51)
Pharmacotherapy improves treatment outcome in depressed cocaine addicts. (51)
Long-term changes in current psychiatric diagnoses of treated opiate addicts. (51)
Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers (51)
Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts (51)
Treatment for opioid dependence: quality and access. (50)
Improving Treatment Outcome in Pregnant, Methadone-Maintained Women: Results From a Randomized Clinical Trial (50)
Minocycline attenuates subjective rewarding effects of dextroamphetamine in humans (50)
Suicidality among opioid addicts: 2.5 year follow-up. (50)
A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. (50)
Efficacy of Opiate Maintenance Therapy and Adjunctive Interventions for Opioid Dependence with Comorbid Cocaine Use Disorders: A Systematic Review and Meta-Analysis of Controlled Clinical Trials (50)
Cigarette Smoking in Male Patients with Chronic Schizophrenia in a Chinese Population: Prevalence and Relationship to Clinical Phenotypes (50)
Nicotine dependence and serum BDNF levels in male patients with schizophrenia (49)
Elevated plasma superoxide dismutase in first-episode and drug naive patients with schizophrenia: Inverse association with positive symptoms (49)
Update on pharmacotherapy for treatment of opioid use disorder (48)
Cigarette Smoking and Cognitive Function in Chinese Male Schizophrenia: A Case-Control study (48)
The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: A pilot study. (48)
Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. (48)
Desipramine in opioid-dependent cocaine abusers maintained on buprenorphine vs methadone. (47)
Serum testosterone differences between patients with schizophrenia and those with affective disorder (47)
Editorial: Challenges to Opioid Use Disorders During COVID‐19 (47)
A single-blind investigation of four auricular needle puncture configurations. (47)
Genetics of Dopamine and its Contribution to Cocaine Addiction (47)
Choosing a behavioral therapy platform for pharmacotherapy of substance users. (47)
Brain-Derived Neurotrophic Factor Levels and Its Val66Met Gene Polymorphism Predict Tardive Dyskinesia Treatment Response to Ginkgo Biloba (46)
A field trial of DSM-III-R psychoactive substance dependence disorders. (46)
Emerging drugs for the treatment of cocaine use disorder: a review of neurobiological targets and pharmacotherapy (46)
A vaccine against methamphetamine attenuates its behavioral effects in mice. (46)
Vaccines against stimulants: cocaine and MA (46)
Intravenous cocaine challenges during naltrexone maintenance: A preliminary study (46)
Pharmacologic management of comorbid post-traumatic stress disorder and addictions. (45)
Regional cerebral blood flow during acute and chronic abstinence from combined cocaine-alcohol abuse. (45)
Noradrenergic α1 Receptor Antagonist Treatment Attenuates Positive Subjective Effects of Cocaine in Humans: A Randomized Trial (45)
Circadian Alteration in Neurobiology During 30 Days of Abstinence in Heroin Users (45)
Increased serum S100B in never-medicated and medicated schizophrenic patients. (44)
Performance-based assessment of functional skills in severe mental illness: results of a large-scale study in China. (44)
Attachment Theory and Multiple Dimensions of Grief (43)
Bupropion reduces cocaine abuse in methadone-maintained patients. (43)
Parental Alcoholism in Opioid Addicts (43)
Elevated interleukin-18 serum levels in chronic schizophrenia: Association with psychopathology. (43)
Challenges in increasing access to buprenorphine treatment for opiate addiction. (43)
Time-Dependent Neuroendocrine Alterations and Drug Craving during the First Month of Abstinence in Heroin Addicts (43)
Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans. (43)
Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use (42)
Gender Effects Following Repeated Administration of Cocaine and Alcohol in Humans (41)
Benzodiazepine use in posttraumatic stress disorder among veterans with substance abuse. (41)
Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers (41)
Six‐Month Follow‐Up of Short‐Term Pharmacotherapy for Cocaine Dependence (41)
Nontolerance to the opioid antagonism of naltrexone (41)
Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats (41)
Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics (40)
A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. (40)
The future potential for cocaine vaccines (40)
Vaccines for cocaine abuse (40)
Nicotine Dependence, Symptoms and Oxidative Stress in Male Patients with Schizophrenia (39)
Intravenous cocaine challenges during desipramine maintenance. (39)
Multidimensionality and prediction of treatment outcome in opioid addicts: 2.5-year follow-up. (39)
Urinary‐Free Cortisol Excretion in Relation to Age in Acutely Stressed Persons with Depressive Symptoms (39)
Effects of sham and real auricular needling: implications for trials of acupuncture for cocaine addiction. (39)
Serotonin transporter genotype and mild traumatic brain injury independently influence resilience and perception of limitations in veterans. (38)
Effect of clonidine pretreatment on naloxone-precipitated opiate withdrawal. (38)
Circadian alteration in neurobiology during protracted opiate withdrawal in rats (38)
Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers (38)
The antecedents and benefits of achieving abstinence in opioid addicts: a 2.5-year follow-up study. (38)
Treatment of severe lithium-induced polyuria with amiloride. (37)
Atomoxetine Attenuates Dextroamphetamine Effects in Humans (37)
Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics (37)
Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls (36)
Beta endorphin levels in CSF during methadone maintenance. (36)
Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controls (36)
Preliminary study of buprenorphine and bupropion for opioid-dependent smokers. (35)
Cigarette smoking, psychopathology and cognitive function in first-episode drug-naive patients with schizophrenia: a case-control study (35)
Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: Preliminary findings (35)
Urinary free cortisol and separation anxiety early in the course of bereavement and threatened loss (35)
A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic (35)
Cortical excitability in cocaine-dependent patients: a replication and extension of TMS findings. (35)
Current pharmacotherapies for opioid dependence. (35)
Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine (35)
Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure. (35)
When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments. (35)
Spect regional cerebral blood flow and neuropsychological testing in non-demented HIV-positive drug abusers: Preliminary results (34)
The Use of Psychoendocrine Strategies in Post‐Traumatic Stress Disorder1 (34)
Naltrexone with or without guanfacine for preventing relapse to opiate addiction in St.-Petersburg, Russia. (34)
Sex difference in the prevalence of smoking in Chinese schizophrenia. (34)
Anti-cocaine vaccine development (34)
A 2.5 year follow-up of treatment retention and reentry among opioid addicts. (34)
Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms. (34)
Gender differences in the specificity of alcoholism transmission among the relatives of opioid addicts. (33)
Association of Spirituality and Sobriety During a Behavioral Spirituality Intervention for Twelve Step (TS) Recovery (33)
Buprenorphine for cocaine and opiate dependence. (33)
Evidence for altered desipramine disposition in methadone-maintained patients treated for cocaine abuse. (33)
Cue-elicited cocaine craving and autogenic relaxation. Association with treatment outcome. (33)
A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal. (32)
Relationship of Depression to Psychosocial Stressors in Heroin Addicts (32)
Cocaine-associated panic attacks in methadone-maintained patients. (32)
Pharmacological Blocking Agents for Treating Substance Abuse (32)
The concept of pharmacologic cocaine interception as a treatment for drug abuse. (32)
Psychosis and synthetic cannabinoids (32)
Sensory gating and psychosis vulnerability in cocaine-dependent individuals: preliminary data (32)
A morphine conjugate vaccine attenuates the behavioral effects of morphine in rats (32)
The Lexington narcotic farm. (32)
Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans (32)
Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications (32)
Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits (32)
Combined Cocaine Hydrolase Gene Transfer and Anti-Cocaine Vaccine Synergistically Block Cocaine-Induced Locomotion (32)
Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics (31)
Spontaneous ejaculation associated with anxiety: psychophysiological considerations. (31)
Bereavement and catecholamines. (31)
Psychological Correlates of Growth Hormone Response to Stress (31)
Improving PTSD/substance abuse treatment in the VA: a survey of providers. (31)
Cognitive function and cerebral perfusion during cocaine abstinence. (31)
Use of drug combinations in treatment of opioid withdrawal. (30)
Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse (30)
Association of Catechol‐O‐methyltransferase gene polymorphisms with schizophrenia and negative symptoms in a Chinese population (30)
Pathological gambling. (30)
The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients (30)
Elevated motor threshold in drug-free, cocaine-dependent patients assessed with transcranial magnetic stimulation (30)
Dopaminergic responsivity during cocaine abstinence: a pilot study (29)
Inhibitory behavioral control: A stochastic dynamic causal modeling study comparing cocaine dependent subjects and controls (29)
Developing the tools of implementation science in substance use disorders treatment: applications of the consolidated framework for implementation research. (29)
Euphorigenic doses of cocaine reduce [123I]β-CIT SPECT measures of dopamine transporter availability in human cocaine addicts (29)
Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies (29)
Relationship of marital structure and interactions to opiate abuse relapse. (29)
Opioid Addiction (29)
Serum testosterone levels in post-traumatic stress disorder inpatients (29)
Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. (29)
Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies (29)
Association between self-report of cognitive impairment, HIV status, and cocaine use in a sample of cocaine-dependent methadone-maintained patients. (28)
Cocaine use and the mid-latency auditory evoked responses (28)
Alexithymia as a predictor of treatment response in post‐traumatic stress disorder (28)
Cocaine abuse in methadone maintenance programs: integrating pharmacotherapy with psychosocial interventions. (28)
Pharmacologic management of relapse prevention in addictive disorders. (28)
Minocycline adjunctive treatment to risperidone for negative symptoms in schizophrenia: Association with pro-inflammatory cytokine levels (28)
Family Support and Employment as Predictors of Smoking Cessation Success: A Randomized, Double-Blind, Placebo-Controlled Trial of Nicotine Sublingual Tablets in Chinese Smokers (28)
Progesterone effects on cocaine use in male cocaine users maintained on methadone: a randomized, double-blind, pilot study. (28)
Examining the Effect of Cerebral Perfusion Abnormality Magnitude on Cognitive Performance in Recently Abstinent Chronic Cocaine Abusers (28)
Can you vaccinate against substance abuse? (27)
Buprenorphine for office-based practice: consensus conference overview. (27)
Probing Cocaine-Antibody Interactions in Buffer and Human Serum (27)
Decreased serum brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia (27)
Ketoconazole increases cocaine and opioid use in methadone maintained patients. (27)
Cocaine Use in Buprenorphine-vs. Methadone-Maintained Patients (27)
Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population (27)
An Open Trial of Sertraline for Cocaine Abuse (27)
Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice. (26)
Excessive Appetites: A Psychological View of Additions (26)
Effects of gamma-hydroxybutyric acid (GHB) in opioid-dependent patients. (26)
Extensive white matter abnormalities and clinical symptoms in drug-naive patients with first-episode schizophrenia: a voxel-based diffusion tensor imaging study. (26)
Association between monoamine oxidase (MAO)-A gene variants and schizophrenia in a Chinese population (26)
Effect of rapamycin on cue-induced drug craving in abstinent heroin addicts. (26)
Dopamine and serotonin transporter availability in chronic heroin users: A [123I]β-CIT SPECT imaging study (25)
Withdrawal Symptoms and Nicotine Dependence Severity Predict Virtual Reality Craving in Cigarette-Deprived Smokers. (25)
Can Cocaine Craving Be a Medication Development Outcome (25)
Gender differences in socio-demographic and clinical characteristics of methamphetamine inpatients in a Chinese population. (25)
Clinician's guide to cocaine addiction : theory, research, and treatment. (25)
Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial. (25)
Serum Thyroxine Levels in Schizophrenic and Affective Disorder Diagnostic Subgroups (25)
Smoking and Serum Lipid Profiles in Schizophrenia (25)
Stereotactic Neurosurgical Treatment of Drug Addiction (25)
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine (25)
Prescription pain medication dependence. (25)
Spontaneous development of IgM anti-cocaine antibodies in habitual cocaine users: effect on IgG antibody responses to a cocaine cholera toxin B conjugate vaccine. (25)
Diabetes and Cognitive Deficits in Chronic Schizophrenia: A Case-Control Study (24)
Behavioral effects of γ-hydroxybutyrate in humans (24)
Reduction of opiate withdrawal-like symptoms by cocaine abuse during methadone and buprenorphine maintenance. (24)
The type 2 diabetes mellitus susceptibility gene IGF2BP2 is associated with schizophrenia in a Han Chinese population. (24)
Can Cocaine Craving Be a Medication Development Outcome?: Drug Craving and Relapse in Opioid and Cocaine Dependence (24)
The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders (24)
Family Denial as a Prognostic Factor in Opiate Addict Treatment Outcome (24)
Methadone dose for cocaine abuse. (24)
Association between the 5-HTR1B gene polymorphisms and alcohol dependence in a Han Chinese population (24)
Treatment of dual diagnosis patients: a relapse prevention group approach. (24)
Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia (24)
Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage. (24)
ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse (24)
The effect of lamotrigine on naloxone-precipitated opiate withdrawal. (23)
Spirituality and Confidence to Resist Substance Use Among Celebrate Recovery Participants (23)
Use of alternative medicine in major depression. (23)
Immunotherapy for drug abuse. (23)
The effect of alcohol on the neuropsychological functioning of recently abstinent cocaine-dependent subjects. (23)
Severity of precipitated opiate withdrawal predicts drug dependence by DSM-III-R criteria. (23)
New medication strategies for comorbid substance use and bipolar affective disorders (23)
Effect of alpha-methyl-para-tyrosine on response to cocaine challenge (23)
Clinical Efficacy of Sertraline Alone and Augmented With Gabapentin in Recently Abstinent Cocaine-Dependent Patients With Depressive Symptoms (23)
The dexamethasone suppression test during bereavement. (23)
Pharmacogenetic randomized trial for cocaine abuse: Disulfiram and α1A -adrenoceptor gene variation (23)
Cocaine Withdrawal Symptoms Predict Medication Response in Cocaine Users (23)
Desipramine, amantadine, or fluoxetine in buprenorphine-maintained cocaine users. (23)
Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia (23)
Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. (23)
Modifying the role of serotonergic 5‐HTTLPR and TPH2 variants on disulfiram treatment of cocaine addiction: a preliminary study (22)
DBH gene as predictor of response in a cocaine vaccine clinical trial (22)
Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment. (22)
Association of BDNF gene polymorphisms with schizophrenia and clinical symptoms in a Chinese population (22)
The Impact of Disulfiram Treatment on the Reinforcing Effects of Cocaine: A Randomized Clinical Trial (22)
Smoking and tardive dyskinesia in male patients with chronic schizophrenia (22)
Reliability of sequential naloxone challenge tests. (22)
A national survey of clinicians’ views of evidence-based therapies for PTSD and substance abuse (22)
The future of vaccines in the management of addictive disorders (22)
Stress Enhances Retrieval of Drug-Related Memories in Abstinent Heroin Addicts (22)
Inappropriate secretion of antidiuretic hormone in a patient receiving piperazine phenothiazines. (22)
Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia (22)
New treatments for opiate dependence (21)
Diurnal variation in cue-induced responses among protracted abstinent heroin users (21)
Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids. (21)
A Review of Pharmacotherapies for Substance Abuse (21)
Current status and future prospects for the development of substance abuse vaccines (21)
Prevalence, demographic and clinical correlates of suicide attempts in Chinese medicated chronic inpatients with schizophrenia. (21)
Perceived marital and family environment of opiate addicts. (21)
Buprenorphine: beyond methadone? (21)
A Conjugate Vaccine Attenuates Morphine- and Heroin-Induced Behavior in Rats (21)
The Effect of Gamma-Hydroxybutyric Acid on Naloxone-Precipitated Opiate Withdrawal (21)
Therapeutic vaccines for substance dependence. (21)
The &kgr;-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial (21)
Addiction as a brain disease. (20)
Rapid detoxification from opioid dependence. (20)
Measuring alcohol consumption among older adults: a comparison of available methods. (20)
Increased habenular connectivity in opioid users is associated with an &agr;5 subunit nicotinic receptor genetic variant (20)
The effect of minocycline on amelioration of cognitive deficits and pro-inflammatory cytokines levels in patients with schizophrenia (20)
Insular resting state functional connectivity is associated with gut microbiota diversity (20)
Lower serum interleukin-2 levels in schizophrenic patients with tardive dyskinesia (19)
Going from the bedside back to the bench with ecopipam: a new strategy for cocaine pharmacotherapy development (19)
Riluzole and d-amphetamine interactions in humans (19)
Neuroleptic Use in the Treatment of Post-Traumatic Stress Disorder (19)
Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study. (19)
[123I]β-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts (19)
Association of the manganese superoxide dismutase gene Ala–9Val polymorphism with clinical phenotypes and tardive dyskinesia in schizophrenic patients (19)
Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report. (19)
Alpha oscillations in response to affective and cigarette-related stimuli in smokers. (19)
Association between DBH 19bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients (18)
A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings. (18)
Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. (18)
Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls. (18)
The prevalence and clinical‐demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine (18)
Serum Cortisol Secretion During Heroin Abstinence Is Elevated Only Nocturnally (18)
Smoking initiation and schizophrenia: A replication study in a Chinese Han population (18)
BDNF Val66Met Variant and Smoking in a Chinese Population (18)
The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. (18)
Altered methamphetamine place conditioning in mice vaccinated with a succinyl-methamphetamine-tetanus-toxoid vaccine. (18)
Neurobiological Adaptations to Psychostimulants and Opiates as a Basis of Treatment Development (18)
Buprenorphine Prescribing: To Expand or Not to Expand (17)
The Interaction of Polymorphisms of IL10 and DBH Was Associated with General Symptoms of PANSS with TD in Chinese Han Schizophrenic Patients (17)
Treatment of heroin (diamorphine) addiction: current approaches and future prospects. (17)
Position statement on methadone maintenance treatment. (17)
Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: a case-control study. (17)
Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. (17)
Abstinence symptomatology associated with cessation of chronic cocaine abuse among methadone-maintained patients. (17)
Gender-specific vulnerability for rCBF abnormalities among cocaine abusers (17)
Differential cigarette-related startle cue reactivity among light, moderate, and heavy smokers. (17)
Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. (17)
Effect of LAAM dose on opiate use in opioid-dependent patients. A pilot study. (17)
Desipramine treatment for cocaine dependence in buprenorphine- or methadone-treated patients: baseline urine results as predictor of response. (17)
Genetic variation of the dopamine transporter (DAT1) influences the acute subjective responses to cocaine in volunteers with cocaine use disorders (17)
Effect of Methadone Dose on Cocaine Abuse in a Methadone Program (17)
Tiagabine affects the subjective responses to cocaine in humans (17)
Predictors of 2.5-year outcome in opioid addicts: pretreatment source of income. (16)
Gender differences in the prevalence of diabetes mellitus in chronic hospitalized patients with schizophrenia on long-term antipsychotics (16)
Effects of ethnicity on low-dose opiate stabilization. (16)
Disulfiram enhances subjective effects of dextroamphetamine in humans (16)
Dual diagnoses: substance abuse and personality disorders. (16)
Effects of Lamotrigine on Behavioral and Cardiovascular Responses to Cocaine in Human Subjects (16)
Serum thyroxine change and clinical recovery in psychiatric inpatients (16)
Bromocriptine treatment of cocaine abuse in patients maintained on methadone. (15)
Crossover Trial of Mazindol for Cocaine Dependence (15)
Naloxone challenge as a biological predictor of treatment outcome in opiate addicts. (15)
The influence of dopamine &bgr;-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study (15)
The Val66Met polymorphism of the brain-derived neurotrophic factor gene is not associated with risk for schizophrenia and tardive dyskinesia in Han Chinese population (15)
Platelet abnormalities associated with cerebral perfusion defects in cocaine dependence (15)
Decreased Digital Flow Persists After the Abatement of Cocaine-Induced Hemodynamic Stimulation (15)
Mental health services for infectious disease outbreaks including COVID-19: a rapid systematic review (15)
Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits. (15)
A 2.5-year follow-up of short-term interpersonal psychotherapy in methadone-maintained opiate addicts. (15)
Changes concurrent with initiation of abstinence from cocaine abuse. (15)
Association of functional dopamine-beta-hydroxylase (DBH) 19bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers (15)
Effects of acute buprenorphine on responses to intranasal cocaine: a pilot study. (15)
Association of the dopamine β‐hydroxylase 19 bp insertion/deletion polymorphism with positive symptoms but not tardive dyskinesia in schizophrenia (14)
Cocaine Precipitation of Patient-Identified Opiate Withdrawal (14)
ZNF804A variants confer risk for heroin addiction and affect decision making and gray matter volume in heroin abusers (14)
Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population (14)
Dose dependent effects of yohimbine on methadone maintained patients. (14)
Hapten Optimization for Cocaine Vaccine with Improved Cocaine Recognition (13)
Altered anterior cingulate cortex to hippocampus effective connectivity in response to drug cues in men with cocaine use disorder (13)
Antisocial personality and stress-induced brain activation in cocaine-dependent patients (13)
Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal (13)
The SCID: a clinical instrument for assessing psychiatric disorders. (13)
Cannabinoid antagonists: a treatment in search of an illness. (13)
The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia. (13)
Treatment of Heroin (Diamorphine) Addiction (13)
Sex Differences in Self-Reported and Physiological Response to Oral Cocaine and Placebo in Humans (12)
Influence of treatment readiness on outcomes of two pharmacotherapy trials for cocaine abuse among methadone-maintained patients. (12)
Motivational factors in cocaine pharmacotherapy trials with methadone-maintained patients: problems and paradoxes. (12)
Association between TNF-α promoter −308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia (12)
Multidimensional hormonal discrimination of paranoid schizophrenic from bipolar manic patients (12)
Aripiprazole treatment of risperidone-induced hyperprolactinemia. (12)
The MTHFR C677T Variant is Associated with Responsiveness to Disulfiram Treatment for Cocaine Dependency (12)
Therapeutic options and challenges for substances of abuse (12)
Alexithymia as a predictor of treatment response in post-traumatic stress disorder (12)
Acute bereavement, threatened loss, ego defenses and adrenocortical function. (12)
Serum concentrations of circulating thyroid hormones in a group of depressed men. (12)
Baclofen-assisted detoxification from opiates. A pilot study. (12)
Guanine nucleotide binding proteins in opioid-dependent patients (12)
Designing Drug Efficacy Trials in the Treatment of Cocaine Abuse (12)
Use of cocaine to prevent opiate withdrawal. (11)
The effect of multiple family therapy on addict family functioning: a pilot study. (11)
New treatments for chemical addictions (11)
Naltrexone for Initiation and Maintenance of Opiate Abstinence (11)
Aspirin or amiloride for cerebral perfusion defects in cocaine dependence. (11)
Extract of Ginkgo biloba is equivalent to vitamin E in attenuating and preventing vacuous chewing movements in a rat model of tardive dyskinesia. (11)
A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study (11)
Subjective and Cardiovascular Effects of Intravenous Methamphetamine during Perindopril Maintenance: A Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study (11)
Relationship of depression to clonidine detoxification of opiate addicts. (11)
Pharmacotherapy for Stimulant-Related Disorders (11)
Hydromorphone-naloxone combinations in opioid-dependent humans under a naloxone novel-response discrimination procedure. (11)
Operationalizing NIMH Research Domain Criteria (RDoC) in naturalistic clinical settings. (11)
Brain-derived neurotrophic factor polymorphisms and smoking in schizophrenia (11)
Preclinical efficacy of an anti‐methamphetamine vaccine using E6020 adjuvant (11)
Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T. (11)
Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China. (11)
Inhibitory Behavioral Control: A Stochastic Dynamic Causal Modeling Study Using Network Discovery Analysis (11)
Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: Low doses induce hypolocomotion (10)
Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers (10)
Double-blind evaluation of the effect of acute amantadine on cocaine craving (10)
Interactions of cocaine with nimodipine: a brief report. (10)
The predictive validity of the dependence syndrome in opiate abusers. (10)
Current concepts in pharmacotherapy of substance abuse (10)
Recent Advances in Detoxification and Maintenance Therapy (10)
Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated schizophrenic patients (10)
Platelet α‐Granule Release in Cocaine Users (10)
Naltrexone induction: psychologic and pharmacologic strategies. (10)
Pharmacogenetic role of dopamine transporter (SLC6A3) variation on response to disulfiram treatment for cocaine addiction. (9)
Alcohol and cocaine abuse. A comparison of epidemiology and clinical characteristics. (9)
Alcohol and Cocaine Abuse (9)
Buprenorphine for the treatment of posttraumatic stress disorder (9)
Desipramine and its 2-hydroxy metabolite in patients taking or not taking methadone. (9)
Intensive community-focused treatment of veterans with dual diagnoses. (9)
The pharmacotherapy of relapse prevention using anticonvulsants. (9)
The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers (9)
Pemoline for the treatment of cocaine dependence in methadone-maintained patients. (9)
Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients. (8)
Alcoholism and depressive disorders in opioid addicts and their family members. (8)
An open pilot study of bupropion and psychotherapy for the treatment of cocaine abuse in methadone-maintained patients. (8)
Individual differences in humans responding under a cocaine discrimination procedure: discriminators versus nondiscriminators. (8)
Complementary marital roles of male heroin addicts: evolution and intervention tactics. (8)
The Pharmacotherapy of Cocaine Dependence (8)
The VA Psychiatry-Primary Care Education Initiative (8)
Elevated serum levels of tumor necrosis factor-α in clozapine-associated obesity in chronic schizophrenia (8)
Stress and addiction. (8)
High‐ and low‐dose Mazindol for cocaine dependence in methadone‐maintained patients: A preliminary evaluation (8)
Anti-addiction vaccines (8)
Serum IL-18 level, clinical symptoms and IL-18-607A/C polymorphism among chronic patients with schizophrenia in a Chinese Han population (8)
Potential Toxicities of High Doses of Naltrexone in Patients with Appetitive Disorders (8)
Risperidone for Substance Dependent Psychotic Patients (8)
Genome-Wide Association Studies of Schizophrenia and Bipolar Disorder in a Diverse Cohort of US Veterans. (8)
Cocaine abuse among methadone-maintained patients. (7)
An Opioid for Depression? (7)
Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. (7)
D-cycloserine-Naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure. (7)
Attenuation of cocaine-induced locomotor activity in male and female mice by active immunization. (7)
Reinforcement sensitivity underlying treatment-seeking smokers' affect, smoking reinforcement motives, and affective responses. (7)
Utility of crossover designs in clinical trials: efficacy of desipramine vs. placebo in opioid-dependent cocaine abusers. (7)
Association of functional COMT Val108/Met polymorphism with smoking cessation in a nicotine replacement therapy (7)
Buprenorphine for Opioid Detoxification: A Brief Review (7)
The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic. (7)
Dopamine D3 receptor-preferring agonist enhances the subjective effects of cocaine in humans (6)
Pharmacogenetics of Dopamine β‐Hydroxylase in cocaine dependence therapy with doxazosin (6)
Abuse of cocaine with opioids: psychological aspects of treatment. (6)
PATHOPHYSIOLOGY AND TREATMENT OF COCAINE DEPENDENCE (6)
The dependence syndrome concept as applied to alcohol and other substances of abuse. (6)
AMA Discharges: Prediction and Treatment Outcome (6)
Mental and neurological disorders and risk of COVID-19 susceptibility, illness severity and mortality: A systematic review, meta-analysis and call for action (6)
Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research (6)
The potential of pharmacogenomics to treat drug addiction. (6)
Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia. (6)
Guanfacine Attenuates Adverse Effects of Dronabinol (THC) on Working Memory in Adolescent-Onset Heavy Cannabis Users: A Pilot Study. (6)
Active immunotherapy for the Treatment of Cocaine Dependence. (6)
Internet Addiction Increases in the General Population During COVID‐19: Evidence From China (6)
Mental Health Status of Adolescents after Family Confinement During the COVID-19 Outbreak (6)
Orbitofrontal, dorsal striatum, and habenula functional connectivity in psychiatric patients with substance use problems. (6)
General Approaches to Substance and Polydrug Use Disorders (5)
The Organization of a Methadone Maintenance Program (5)
The dependence syndrome across different psychoactive substances: revised DSM-III. (5)
Pharmacotherapy of stimulant dependence: one of Japan's greatest public health challenges. (5)
Coordination of medical care and opioid dependence treatment in primary care: A case report (5)
Examining the utility of using genotype and functional biology in a clinical pharmacology trial: pilot testing dopamine β-hydroxylase, norepinephrine, and post-traumatic stress disorder. (5)
Doxazosin treatment in cocaine use disorder: pharmacogenetic response based on an alpha-1 adrenoreceptor subtype D genetic variant (5)
Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus (5)
Guidelines for prevention and treatment of internet addiction in adolescents during home quarantine for the COVID-19 pandemic (5)
One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia (5)
Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review. (5)
Exenatide once weekly for smoking cessation: study protocol for a randomized clinical trial (5)
FAAH variant Pro129Thr modulates subjective effects produced by cocaine administration (5)
Smoking reduction and quality of life in chronic patients with schizophrenia in a Chinese population--A pilot study. (4)
Source of income as a predictor in opioid addicts: 2.5 year follow-up. (4)
Substance Abuse: Clinical Problems and Perspectives (4)
Moderators of response to sertraline versus placebo among recently abstinent, cocaine dependent patients: A retrospective analysis of two clinical trials (4)
704 Longitudinal safety and immunogenicity of a therapeutic cocaine vaccine (4)
PHARMACOLOGICAL APPROACHES TO COCAINE DEPENDENCE (4)
Drugs for Cocaine Dependence: Not Easy-Reply (4)
Association of Symptoms of Attention Deficit and Hyperactivity with Problematic Internet Use among University Students in Wuhan, China During the COVID-19 Pandemic. (4)
Opioid Use Disorder After Self-medicating Pain From Traumatic Brain Injury. (4)
Comments on Ross & Darke's "The nature of benzodiazepine dependence among heroin users". (4)
Buprenorphine for benzodiazepine-abusing heroin addicts. (4)
DRUGS FOR COCAINE DEPENDENCE : NOT EASY. AUTHOR'S REPLIES (4)
Lack of association between the BDNF C270T polymorphism and schizophrenia in a Chinese Han population (4)
The &agr;-1 adrenoceptor (ADRA1A) genotype moderates the magnitude of acute cocaine-induced subjective effects in cocaine-dependent individuals (4)
Cocaine and Methamphetamine Dependence: Advances in Treatment (4)
Addictive States. Research Publications: Association for Research in Nervous and Mental Disease, Volume 70 (4)
Researcher experiences with IRBs: a survey of members of the American College of Neuropsychopharmacology. (4)
Diagnosing depression with the DST and TRH in cocaine and opioid abusers. (3)
No association between the type 2 diabetes mellitus susceptibility gene, SLC30A8 and schizophrenia in a Chinese population (3)
The CCR5 32-bp deletion allele is rare in a Chinese population (3)
Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine depend (3)
Use predicts treatment outcome, not opiate dependence or withdrawal. (3)
Current status of immunotherapies for addiction (3)
Next Generation Programmable Bio-Nano-Chip System for On-Site Detection in Oral Fluids. (3)
Pharmacotherapeutic Environments for Substance use Disorders (3)
Marie Nyswander, 1919–1986 (3)
Lofexidine in Combination with Oral Naltrexone for Opioid Use Disorder Relapse Prevention: A pilot Randomized, Double-Blind, Placebo-Controlled Study. (3)
Chronic naltrexone effect on cortisol. (3)
Vaccines in the Treatment of Substance Abuse. (3)
Consequences of Adolescent Drug Use: Impact on the Lives of Young Adults (3)
Cognitive Deficits and Clinical Symptoms with Hippocampal Subfields in First-Episode and Never-Treated Patients with Schizophrenia. (3)
Programmable bio-nano-chip system for saliva diagnostics (3)
Gender Differences in Cocaine and Treatment Response Use (3)
Next Generation Programmable Bio-Nano-Chip System for On-Site Quantitative Drug Detection in Oral Fluids (3)
Prescription Opioid Misuse: Effective Methods for Reducing the Epidemic (3)
The relationship of the Maudsley Personality Inventory to depression in addicts. (3)
Clinical Management: Cocaine (2)
Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge (2)
AMPT Effects on Cue-Induced Craving for Cocaine (2)
Long-Term Impact of COVID-19 on Mental Health among the General Public: A Nationwide Longitudinal Study in China (2)
New Medication Strategies for Comorbid Substance Use and Bipolar Affective Disorders (2)
Naltrexone Induced Appetite Suppression and Weight Loss (2)
Hospital Stay in Synthetic Cannabinoid Users With Bipolar Disorder, Schizophrenia, or Other Psychotic Disorders Compared With Cannabis Users. (2)
Vaccines for Treating Cocaine Use Disorders (2)
Nontolerance of Naltrexone to the Opioid Antagonism (2)
Near syncope associated with concomitant clozapine and cocaine use. (2)
Psychopharmacology: neuroimmune signaling in psychiatric disease-developing vaccines against abused drugs using toll-like receptor agonists (2)
Use of Guanfacine for Cannabis use Disorder and Related Symptomology. (2)
Peptide T Treatment of Cognitive Impairment in HIV-Positive Intravenous Drug Users (2)
Human Laboratory and Neuroimaging Studies in Substance Use Disorders: Developing New Treatment Approaches (2)
Cocaine symptoms are predicted by familial psychopathology. (2)
Treatment for Opioid Dependence (1)
Neurobiology of Opioid Use Disorder and Comorbid Traumatic Brain Injury (1)
A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336 (1)
Response to Lustman et al. Letter (1)
Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long-acting sustained-release naltrexone implant (1)
Inpatient vs. outpatient cocaine abuse treatments. (1)
Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions (1)
Buprenorphine for Opioid and Cocaine Dependence (1)
Revisiting the Hallucinogenic Potential of Ketamine (1)
Programmable Bio-Nano-Chips for the quantitation of drugs of abuse in oral fluids (1)
Treating Addiction to Prescription Opioids. (1)
What are America's opportunities for harm reduction strategies in opiate dependence? (1)
Dual dependency on cocaine and alcohol in opiate addicts: treatment options. (1)
Preliminary Investigation of Selegiline for the Treatment of Cocaine Dependence (1)
Exenatide Adjunct to Nicotine Patch Facilitates Smoking Cessation and May Reduce Post-Cessation Weight Gain: a Pilot Randomized Controlled Trial. (1)
Altered habenula resting state functional connectivity in deprived veteran tobacco smokers: A pilot study. (1)
Antidepressants in the treatment of PTSD. (1)
Vaccines for Methamphetamine Use Disorder (1)
The angiotensin receptor blocker candesartan attenuates the subjective effects of methamphetamine in humans (1)
Pharmacotherapies for Cocaine Dependence (1)
Anti-cocaine vaccine (1)
PTSD AND SUBSTANCE ABUSE : EPIDEMIOLOGY, GENETICS AND NEUROBIOLOGY (1)
Alcohol and Other Substance Use Disorders (1)
Advances in the pharmacotherapy of stimulant dependence: From alcohol antagonists to Xenova vaccines (1)
PHENELZINE OR IMIPRAMINE IN POSTTRAUMATIC STRESS DISORDER (1)
Faculty Opinions recommendation of A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14 C-morphine binding. (1)
Preclinical efficacy of an anti-methamphetamine vaccine with an E6020 adjuvant (1)
Immunotherapies To Treat Drug Addiction (1)
Pharmacotherapy for Addictions: Partnering with Contingency Management (1)
New Hot Topics Sections: 1. China's New March Forward in Addiction Treatment: Methadone for the Masses 2. Issues in Formulating DSM V (1)
Emerging Treatments and Pharmacogenetics for Cocaine Use Disorder (1)
Use of clonidine for dysmenorrhea in four patients. (1)
Process genes list: An approach to link genetics and human brain imaging (1)
Regular article Consensus statement on office-based treatment of opioid dependence using buprenorphine B (1)
Anti-methamphetamine vaccine attenuates brain levels and locomotor activity of methamphetamine in mice (1)
Couples therapy with cocaine abusers.: (422232004-001) (1)
Psychopathology and personality traits associated with driving while intoxicated in Beijing, China: Implications for interventions (1)
Vaccines for the treatment of cocaine dependence (1)
Mediators of response to sertraline vs. placebo among recently abstinent, cocaine-dependent patients (1)
Anti-methamphetamine vaccine attenuates reinstatement of conditioned place preference in mice (0)
Poster #33 CHANGES IN RESTING STATE CONNECTIVITY FOLLOWING TREATMENT IN FIRST EPISODE SCHIZOPHRENIA (0)
Vaccines for Addictive Disorders (0)
Cigarette Smoking, Psychopathology, Cognitive Function and Medication Side Effects in Chinese Male Schizophrenia: A Case-Control Study (0)
Faculty of 1000 evaluation for New treatments for cocaine dependence: a focused review. (0)
Faculty Opinions recommendation of Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. (0)
Faculty of 1000 evaluation for The methamphetamine problem in the United States. (0)
Nicotine Inhalation and Suicide: Clinical Correlates and Behavioral Mechanisms. (0)
Faculty of 1000 evaluation for Treatment of nicotine addiction: present therapeutic options and pipeline developments. (0)
Special Issue on Diversity, Alcohol, and Genetics. (0)
Pharmacogenetic Treatments for Alcohol and Stimulants (0)
2020 Year in Review: A Look Back With an Eye Toward the Future. (0)
A Review of Pharmacotherapie for Substance Abuse (0)
Comparing Buprenorphine and Methadone Maintenance (0)
Effective connectivity of attentional bias in cocaine dependence (0)
High-Voltage Power Lines: Are Victorians at Risk? (0)
A randomized trial of safety and pharmacodynamic interactions between a selective glucocorticoid receptor antagonist, PT150, and ethanol in healthy volunteers (0)
Are We Making Any Progress in Treatment and Attitudes (0)
Cingulate Cortex Structural Alterations in Substance Use Disorder Psychiatric Inpatients. (0)
Cambridge Textbook of Effective Treatments in Psychiatry: Treatment of stimulant dependence (0)
Repurposed Medications Show Promise in Stimulant Dependence (0)
Mandatory Drug Testing Needs Controlled Evaluation (0)
Faculty Opinions recommendation of Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. (0)
"Just one bad high:" considering synthetic cannabinoid outcome expectancies in adolescents. (0)
Faculty Opinions recommendation of Antibodies to BSA conjugates of morphine derivatives: strict dependency of the immunological specificity on the hapten structure. (0)
Issue Information - Editorial Board. (0)
General Approaches to Substance Use Disorders (0)
A Year in Review: Update of Progress, Changes, and Future Directions (0)
Medications development and the war on drugs: Victims of the gulf war? (0)
Inhibitory control: A brain connectivity study comparing cocaine-dependent subjects and controls (0)
Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia, Bipolar Disorder, and Depression in the VA Health Care System (0)
Welcome to a New Editorial Generation (0)
Issues in Designing and Conducting Clinical Trials for Reward Disorders: A Clinical View (0)
Introduction: Cautions, Considerations, and Treatment Strategies (0)
Evidence-Based Pharmacotherapy for Cocaine, Amphetamine, and Methamphetamine Use Disorders (0)
Coordination of Medical Care and Opioid Dependence Treatment in Primary Care: A Case Report (0)
Incentives for Abstinence Scale (0)
New Insights on Substance Use Disorders (0)
Pharmacologic Management of Comorbid Post-Traumatic Stress Disorder and Addictions. (0)
A Systematic Review and Meta-Analysis on Prevalence of and Risk Factors Associated With Depression, Anxiety and Insomnia in Infectious Diseases, Including COVID-19: A Call to Action (0)
The influence of dopamine B-hydroxylase gene polymorphism −1021C Ç T on levodopa/carbidopa treatment for cocaine dependence: A preliminary study (0)
Virtual reality-induced craving for cigarettes among abstinent smokers (0)
P.6.d.004 Pharmacogenetics of treatment of opioid dependence with oral naltrexone and long acting sustained release naltrexone implant (0)
Connecticut Mental Health Center: Clinical, Research and Training Programs in the Addictions (0)
A Randomized Controlled Trial of Auricular Acupuncture for Cocaine Dependence: Treatments vs Outcomes—Reply (0)
Needs Assessment on Co-Occuring PTSD and Substance Abuse Treatment in VA: (517302011-419) (0)
66. Neuropsychological function during smoking cessation in schizophrenia (0)
Genetic variants of the dopaminergic system associated with subjective responses to cocaine (0)
Faculty of 1000 evaluation for Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. (0)
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. (0)
Revisiting the Hallucinogenic Potential of Ketamine A Case Built on Current Research Findings (0)
Adjuvants for Substance Abuse Vaccines (0)
Faculty Opinions recommendation of Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. (0)
Interaction of gender and genetics in response to cocaine vaccine (0)
Response to Sherry Leonard and Laura Giordano's Letter (0)
Cognitive and cardiovascular effects of carvedilol in recently abstinent, cocaine-dependent patients (0)
[A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence]. (0)
Pharmacogenetics of buprenorphine therapy of cocaine addiction (0)
Editorial: A new partnership with the AAAP newsletter. (0)
Faculty of 1000 evaluation for The rise of methamphetamine in Southeast and East Asia. (0)
Images in psychiatry. Marie Nyswander, 1919-1986. (0)
Editorial: The Year in Review Amidst the COVID-19 Crisis. (0)
Faculty Opinions recommendation of A vaccine against nicotine for smoking cessation: a randomized controlled trial. (0)
Humanized mouse models to study effects of anti-cocaine vaccine (0)
Comorbid alcohol use and post-traumatic stress disorders: Pharmacotherapy with aldehyde dehydrogenase 2 inhibitors versus current agents (0)
Suicide Risk in a National VA Sample: Smoking and Behavior Regulation Versus Psychiatric Diagnosis (0)
Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: A Randomized Controlled Trial (0)
Attenuation of depressive symptoms associated with MTHFR during a cocaine vaccine trial (0)
Norepinephrine as a Therapeutic Target for Cocaine Use Disorder (0)
Neurobiology of Stimulants (0)
Erratum: Pharmacotherapeutics for substance-use disorders: A focus on dopaminergic medications (European Journal of Computational Mechanics (2013) 22:12 (1549-68)) (0)
Current status of vaccines for substance use disorders: A brief review of human studies (0)
Chapter 51 The dependence syndrome concept for alcohol and drug abuse (0)
Efficacy and tolerability of doxazosin in psychostimulant-dependent patients (0)
Cognitive performance of patients with opioid use disorder transitioned to extended-release injectable naltrexone from buprenorphine: Post hoc analysis of exploratory results of a phase 3 randomized controlled trial. (0)
Antidrug Vaccines Fact or Science Fiction ? (0)
The Therapeutic Cannabis User: 5 Key Issues (0)
Editorial: Continuing the Partnership of AJA With the AAAP. (0)
Faculty Opinions recommendation of Long-Run Abstinence After Narcotics Abuse: What Are the Odds? (0)
Immunotherapies To Treat Drug Addiction (0)
Therapeutic vaccines for substance dependence (0)
Fatty acid amide hydrolase gene variant influences acute responses to cocaine (0)
Q&A: Clinical Challenges in Substance Use Disorders (0)
among and Gender Differences Opiate Addicts (0)
Circadian alteration in neurobiology during protracted opiate withdrawal (0)
Online Communities for Drug Withdrawal: What Can We Learn? (0)
Dynamic causal modeling in humans offers a novel approach to delineate prefrontal-striatal serotonergic drivers of impulsivity in rats (0)
Evolution of the Journal of the American Academy of Addiction Psychiatry: The American Journal on Addictions. (0)
Faculty of 1000 evaluation for Development of immunopharmacotherapy against drugs of abuse. (0)
Faculty Opinions recommendation of A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. (0)
Association between α-1 adrenergic receptor (ADRA1A) genotype and subjective cocaine effect in cocaine-dependent individuals (0)
Ubjective responses to acute cocaine are moderated by variants of the serotonergic system (0)
Faculty Opinions recommendation of Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. (0)
Association between α-1 adrenergic receptor (ADRA1A) genotype and subjective cocaine effect in cocaine-dependent individuals (0)
Eating Disorders : Part 2 CATEGORY 1 CME Complementary & Alternative Treatments for ADHA (0)
Adrenoceptor variants moderate treatment response of doxazosin for cocaine use disorder (0)
Assessment of medication effects in neuroimaging using quadratic models (0)
Subjective effects produced by cocaine are in association with genetic variants of DAT1 (0)
Faculty Opinions recommendation of Ethical issues in using a cocaine vaccine to treat and prevent cocaine abuse and dependence. (0)
Evaluation of guanfacine administration on cognition in volunteers with cannabis-use disorder (0)
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans (0)
Substance-Related and Addictive Disorders (0)
Concurrent effects of acute intravenous cocaine in context of chronic desipramine in humans. (0)
International Implications of HIV and Substance Abuse (0)
Genomic and Phenomic Correlates of Suicidality Among US Veterans With Schizophrenia or Bipolar Disorder (0)
A Novel Strategy to Identify Genetic/Brain Imaging Interactions Suggests Habenular Connectivity is Associated With Suicidality (0)
456. Cortical excitability in cocaine-dependent subjects; preliminary data (0)
A “Hands On” Guide to Using Naltrexone in Alcohol Addiction (0)
The Role of the Human Laboratory in Drug Abuse Research (0)
Epidemiological trends and the advances of treatments of amphetamine-type stimulants (ATS) in China. (0)
Faculty of 1000 evaluation for An overview of diversion strategies for Australian drug-related offenders (0)
The OPRD1 rs678849 variant influences outcome of disulfiram treatment for cocaine dependency in methadone-maintained patients (0)
The role of genetic polymorphisms on patient response to opioid use disorder therapy with naltrexone and guanfacine (0)
Coronary Heart Disease / Myocardial Infarction Variable Participation of 5-HIT 1-Like Receptors and 5-HT 2 Receptors in Serotonin-Induced Contraction of Human Isolated Coronary Arteries : 5-HTI-Like Receptors Resemble Cloned 5-HT 1 Dp Receptors (0)
COMPARING BUPRENORPHINE AND METHADONE MAINTENANCE. REPLY (0)
Carbamazepine vs. Oxazepam for Benzodiazepine Detoxification in Methadone-Maintained Patients (0)
Epigenetics of drug abuse: predisposition or (0)
COVID-19 Vaccine-Related Psychological Stress Among General Public in China (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Thomas R Kosten?

Thomas R Kosten is affiliated with the following schools:

Yale University
Baylor College of Medicine